CoChat

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Open access
Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R., Caponigro, Giordano · 2018 · Oncotarget
Cited by 93

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

// Sunkyu Kim 1 , Ralph Tiedt 2 , Alice Loo 1 , Thomas Horn 1 , Scott Delach 1 , Steven Kovats 1 , Kristy Haas 1 , Barbara Schacher Engstler 2 , Alexander Cao 1 , Maria Pinzon-Ortiz 1 , Iain Mulford 1 , Michael G. Acker 1 , Rajiv Chopra 3 , Christopher Brain 4 , Emmanuelle di Tomaso 1 , William R. Sellers 1 and Giordano Caponigro 1 1 Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA 2 Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA 3 Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA 4 Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA Correspondence to: Giordano Caponigro, email: giordano.caponigro@novartis.com Keywords: CDK4/6 inhibitor; ribociclib; LEE011; preclinical; selectivity Received: May 22, 2018 Accepted: September 15, 2018 Published: October 16, 2018 ABSTRACT Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer, in combination with an aromatase inhibitor, and is currently being evaluated in several additional trials. Here, we report the preclinical profile of ribociclib. When tested across a large panel of kinase active site binding assays, ribociclib and palbociclib were highly selective for CDK4, while abemaciclib showed affinity to several other kinases. Both ribociclib and abemaciclib showed slightly higher potency in CDK4 -dependent cells than in CDK6 -dependent cells, while palbociclib did not show such a difference. Profiling CDK4/6 inhibitors in large-scale cancer cell line screens in vitro confirmed that RB1 loss of function is a negative predictor of sensitivity. We also found that routinely used cellular viability assays measuring adenosine triphosphate levels as a proxy for cell numbers underestimated the effects of CDK4/6 inhibition, which contrasts with assays that assess cell number more directly. Robust antitumor efficacy and combination benefit was detected when ribociclib was added to encorafenib, nazartinib, or endocrine therapies in patient-derived xenografts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.26215

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 93

Metadata

Authors
Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., Mulford, I., Acker, M. G., Chopra, R., Brain, C., di Tomaso, E., Sellers, W. R., & Caponigro, G.
Venue
Oncotarget
Published
2018-10-16
Volume
9
Issue
81
Pages
35226-35240
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2896664662
Cited by
93
References
19
FWCI
6.59
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. https://app.cochat.ai/papers/10.18632/oncotarget.26215
The paper
Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., Mulford, I., Acker, M. G., Chopra, R., Brain, C., di Tomaso, E., Sellers, W. R., & Caponigro, G. (2018). The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget. https://doi.org/10.18632/oncotarget.26215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.